Cleveland Biolabs Inc. Announces Publication of Studies Identifying Biomarkers of CBLB502's Efficacy as a Radiation Countermeasure
Published: Aug 01, 2012
BUFFALO, N.Y., Aug. 1, 2012 (GLOBE NEWSWIRE) -- Cleveland BioLabs, Inc. (Nasdaq:CBLI) today announced the online publication of studies identifying biomarkers of CBLB502's efficacy as a radiation countermeasure in the Journal of Pharmacology and Experimental Therapeutics, a leading peer-reviewed research journal in the field of pharmacology. The reported studies were conducted by scientists of Cleveland BioLabs in collaboration with researchers at the Armed Forces Radiobiology Research Institute and the F. Edward Hébert School of Medicine at the Uniformed Services University of the Health Sciences, and Roswell Park Cancer Institute.